VisionGate has appointed John Glasspool as Chief Operating and Strategy Officer and to the firm's board of directors. Glasspool is currently a member of the board of directors of Dalcor. In addition, he is an advisor to MIT Newdigs and leads the FoCUS project, looking at pricing and policy for durable oncology therapies. Glasspool's career includes executive and management responsibilities at pharmaceutical companies, including Scotia Pharmaceuticals, Johnson & Johnson, Novartis, Baxter, and Baxalta. Glasspool has also served on the board of directors and as president of Vaccines Europe at the Biotechnology Industry Organization.